Canaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $42.00 Price Target

Canaccord Genuity set a $42.00 price objective on Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note published on Wednesday, November 29th. The brokerage currently has a hold rating on the stock.

Other equities analysts also recently issued research reports about the stock. Mizuho downgraded shares of Pacira Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for the stock from $53.00 to $44.00 in a research note on Wednesday, November 29th. Wedbush reissued a buy rating and set a $80.00 target price on shares of Pacira Pharmaceuticals in a research note on Monday, November 20th. Janney Montgomery Scott set a $27.00 price target on shares of Pacira Pharmaceuticals and gave the company a sell rating in a research note on Thursday, November 16th. Oppenheimer reaffirmed a hold rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Finally, HC Wainwright reaffirmed a buy rating and issued a $52.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $48.86.

Pacira Pharmaceuticals (PCRX) opened at $44.80 on Wednesday. Pacira Pharmaceuticals has a one year low of $29.81 and a one year high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. The firm had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. equities research analysts expect that Pacira Pharmaceuticals will post -0.85 EPS for the current year.

In other news, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. Insiders have sold a total of 69,735 shares of company stock worth $2,692,594 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. purchased a new stake in Pacira Pharmaceuticals during the 2nd quarter valued at $114,000. Benjamin F. Edwards & Company Inc. boosted its position in Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after buying an additional 303 shares during the period. Cubist Systematic Strategies LLC boosted its position in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after buying an additional 1,752 shares during the period. QS Investors LLC purchased a new stake in Pacira Pharmaceuticals during the 2nd quarter valued at $157,000. Finally, Ameritas Investment Partners Inc. boosted its position in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares during the period.

TRADEMARK VIOLATION NOTICE: “Canaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $42.00 Price Target” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://stocknewstimes.com/2017/12/10/pacira-pharmaceuticals-pcrx-pt-set-at-42-00-by-canaccord-genuity.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply